CMS to Release Permanent J-Code for Phesgo™ Injection

Select patients for therapy based on an FDA-approved companion diagnostic test.

Metastatic Breast Cancer
Phesgo™ is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic test.

See prescribing information.

Posted on 11/19/2020